- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
- Drug · Device · Other
- Lead sponsor
- Pharmosa Biopharm Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 14,761
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- bevacizumab with chemotherapy, Pleur-XTM catheter placement
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypogammaglobulinemia, Lung Transplantation
- Interventions
- IVIG, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Palmitil Inhalation Powder, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more
- Conditions
- Cystic Fibrosis
- Interventions
- Oral Glutathione, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 18
- States / cities
- Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 15 more
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Interventions
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Combination Product
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo
- Biological · Drug · Other
- Lead sponsor
- Immutep S.A.S.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- 16S rRNA stool microbiome sequencing.
- Diagnostic Test
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 0 Days to 7 Days
- Enrollment
- 197 participants
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Anxiety, Depression
- Interventions
- Acceptance-Based Behavior Therapy (ABBT), Treatment-as-Usual (TAU)
- Behavioral · Other
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Durham, North Carolina • Cleveland, Ohio + 1 more
- Conditions
- Coronavirus Infection, Covid-19, SARS-CoV-2
- Interventions
- Ensifentrine Dose 1, Placebo pMDI
- Drug
- Lead sponsor
- Verona Pharma Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Heart Disorder, Lung Disorder, Arthritis
- Interventions
- Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Durham, North Carolina
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661/Ivacaftor, Ivacaftor, Placebo matched to VX-661/ ivacaftor, Placebo matched to Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
- Conditions
- Influenza, Human, COVID-19
- Interventions
- bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,019 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 59
- States / cities
- Athens, Alabama • Phoenix, Arizona • Lake Forest, California + 40 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin, etoposide
- Radiation · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Obesity, Pulmonary Disease, Dyspnea
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Entinostat, Erlotinib
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Small Cell Lung Cancer
- Interventions
- AT-101, topotecan
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
- Conditions
- Pneumonia
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Implementation of Processes
- Procedure
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 16
- States / cities
- Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
- Conditions
- Stage IIIA Non-small Cell Lung Cancer
- Interventions
- paclitaxel, carboplatin, motexafin gadolinium, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
- Interventions
- Retifanlimab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 18
- States / cities
- Fresno, California • San Marcos, California • Santa Rosa, California + 13 more